The Institute for Molecular Medicine Finland (FIMM) is an international research institute focusing on human genomics and personalised medicine at the University of Helsinki. In the beginning of 2017 FIMM joined the University of Helsinki’s new life science research centre, Helsinki Institute of Life Science HiLIFE, as an operational unit. FIMM integrates molecular medicine research, technology centre and biobanking infrastructures under one roof, promoting translational research in grand challenge projects, specifically, the impact of genome information from the Finnish population in personalised health and medicine, individualised cancer medicine, and digital molecular medicine. FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centres for molecular medicine in Norway, Sweden and Denmark, and the EU-LIFE Community.
The INTERVENE consortium (https://www.interveneproject.eu/) is a 5-year 10 million € EU funded project that aims to develop and test next generation tools for disease prevention, diagnosis and personalized treatment utilizing the first US-European pool of genomic and health data and integrating longitudinal and disease-relevant -omics data into genetic risk scores. The consortium includes 18 partners from 11 countries which are closely collaborating together.
The coordinating center at Institute for Molecular Medicine Finland, University of Helsinki is recruiting two fellow positions (post-doc level or higher), that will work in close collaboration with Prof. Samuli Ripatti and Dr. Andrea Ganna. One fellow will be working on the breast cancer clinical pilot, coordinating the multinational study on translating the genetic information to treatment and screening and the other will work on development and application of next generation risk prediction tools.
Professor Samuli Ripatti is a vice-director at FIMM, Professor of Biometry at Faculty of Medicine and a director of Academy of Finland’s Center of Excellence in Complex Disease Genetics. His research group has broad collaboration with international research groups to study genetic variation and its connection to lipids, metabolites and other risk factors for cardiometabolic diseases and common cancers. Professor Ripatti’s group also builds statistical and computational models for complex disease risk estimation. Ripatti has played key roles in major Finnish sequencing efforts. He is the PI of the GeneRISK Study, pioneering studies utilizing personal genetic risk information and returning it to the participants with coaching to lower the risk.
Dr. Andrea Ganna (https://www.dsgelab.org/) is an EMBL-group leader at FIMM and an instructor at Harvard Medical School and Massachusetts General Hospital. His research vision is to integrate genetic data and information from electronic health record/national health registries to enhance early detection of common diseases and public health interventions. Dr. Ganna has been recently awarded with an ERC starting grant to study the application of artificial intelligence methods for prediction of cardiovascular diseases.
Qualification and requirements: We are looking for two future research leaders to work in a highly stimulating international environment with an unprecedented amount of health and genetic information from up to 1.7 million individuals.
The first INTERVENE fellow, who will work on the breast cancer clinical pilot, will have clinical or genetic background with statistics/data science/epidemiological skill set and interest in developing tools to help clinicians and clinical geneticist in making genetically informed decisions in their choices for treatment and cancer screening.
The second INTERVENE fellow, who will work on the development of risk prediction tools, will develop and pilot cutting edge approaches for the next generation of genetic tools for disease prevention, diagnosis, and personalized treatment. The candidates should have a background in statistics, machine learning or related data science. The ideal candidate should have experience in developing or applying cutting-edge methods for genetic prediction based on results from genome-wide association studies and sequencing data.
The candidates should hold a Ph.D. or are about to finish the doctorate studies in the field of genetics, statistics, mathematics, computational sciences, (genetic) epidemiology or clinical medicine. The ideal candidate shows scientific independence, has publishing experience, and an aptitude towards developing novel techniques. Together with the PI, he/she is jointly responsible for coordinating projects and supervising PhD students.
Contract & salary: The job is for a fixed-term of 2-3 years with a possibility of extension. The salary of the position is determined in accordance with the salary system of Finnish universities, and depends on the candidate’s qualifications. The University of Helsinki offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development. A trial period of 6 months will be applied.
How to apply: The application should include cover letter, CV, list of publications, contact information for referees¬. Documents should be submitted as a single PDF file.
To apply, please submit the application through the University of Helsinki electronic recruitment system by clicking on the "Apply for job" link below. Internal applicants (i.e., current employees of the University of Helsinki) please submit your applications through the SAP HR portal. Please apply no later than March 15, 2021.
If you need support with the recruitment system, please contact email@example.com.
Helsinki Institute of Life Science
Helsinki Institute of Life Science (HiLIFE) is a new institute established in 2017 that supports high quality life science research across the University campuses and faculties. HiLIFE builds on existing strengths and new recruits and partnerships to create an attractive international environment for researchers to solve grand challenges in health, food, and environment. HiLIFE coordinates research infrastructures in life sciences and provides research-based interdisciplinary training.
University of Helsinki
The University of Helsinki (UH), founded in 1640, is a vibrant scientific community of 40,000 students and researchers. It is one of the leading multidisciplinary research universities and ranks among the top 100 international universities in the world. It is currently investing heavily in life sciences research. UH offers comprehensive services to its employees, including occupational health care and health insurance, sports facilities, and opportunities for professional development.
15.03.2021 23:59 EET